---
figid: PMC9000317__molecules-27-02259-g004
pmcid: PMC9000317
image_filename: molecules-27-02259-g004.jpg
figure_link: /pmc/articles/PMC9000317/figure/molecules-27-02259-f004/
number: Figure 4
figure_title: ''
caption: 'Alpelisib inhibition of PI3K/AKT signaling pathway (the “x” on the arrows
  indicates process inhibition). RTK: receptor tyrosine kinase. RAS: rat sarcoma viral
  oncogene homolog. PI3K-α: phosphatidylinositol 3-kinase alpha. PIP2: phosphatidylinositol
  4,5-bisphosphate. PIP3: phosphatidylinositol-3,4,5-trisphosphate. PTEN: phosphatase
  and tensin homolog deleted on chromosome ten. PDK: 3-phosphoinositide-dependent
  protein kinase. AKT: protein kinase B. mTORC1: mammalian target of rapamycin complex
  1. 4E-BP1: 4E-binding protein 1. eIF4E: eukaryotic translation initiation factor
  4E. S6K: p70S6 kinase. S6: S6 protein. Created with BioRender.com based on information
  in Ref. [].'
article_title: FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from
  Early 2011 to the End of 2021.
citation: Aleksandra Sochacka-Ćwikła, et al. Molecules. 2022 Apr;27(7):2259.
year: '2022'

doi: 10.3390/molecules27072259
journal_title: Molecules
journal_nlm_ta: Molecules
publisher_name: MDPI

keywords:
- anticancer drugs
- small molecule agents
- solid cancers
- approval characteristic
- FDA
- EMA

---
